Amicus Therapeutics, Inc. (NASDAQ:FOLD) COO Bradley L. Campbell sold 2,500 shares of the business’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $16.01, for a total value of $40,025.00. Following the transaction, the chief operating officer now owns 341,264 shares in the company, valued at approximately $5,463,636.64. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of NASDAQ FOLD opened at $15.83 on Friday. Amicus Therapeutics, Inc. has a twelve month low of $6.25 and a twelve month high of $16.13. The company has a debt-to-equity ratio of 0.50, a quick ratio of 4.31 and a current ratio of 4.45. The company has a 50 day moving average of $13.66 and a 200 day moving average of $11.02.
Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.07). The business had revenue of $60.53 million during the quarter, compared to the consensus estimate of $57.21 million. Amicus Therapeutics had a negative return on equity of 63.24% and a negative net margin of 155.73%. On average, sell-side analysts forecast that Amicus Therapeutics, Inc. will post -1.06 EPS for the current fiscal year.
Several equities analysts have commented on the company. BidaskClub raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 30th. BTIG Research started coverage on shares of Amicus Therapeutics in a research report on Tuesday, June 16th. They set a “buy” rating and a $19.00 price target for the company. Chardan Capital restated a “hold” rating and issued a $12.50 price objective on shares of Amicus Therapeutics in a report on Saturday, May 9th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Amicus Therapeutics in a research note on Monday, June 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Amicus Therapeutics in a research report on Tuesday, June 16th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $19.08.
Hedge funds have recently made changes to their positions in the company. Bank of Montreal Can lifted its position in Amicus Therapeutics by 314.5% during the fourth quarter. Bank of Montreal Can now owns 93,398 shares of the biopharmaceutical company’s stock valued at $910,000 after purchasing an additional 70,868 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Amicus Therapeutics by 3.6% during the 4th quarter. Bank of New York Mellon Corp now owns 2,255,081 shares of the biopharmaceutical company’s stock valued at $21,965,000 after buying an additional 78,720 shares during the period. State Street Corp boosted its stake in shares of Amicus Therapeutics by 1.2% in the 1st quarter. State Street Corp now owns 11,129,151 shares of the biopharmaceutical company’s stock worth $102,833,000 after buying an additional 132,427 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Amicus Therapeutics by 92.8% in the 4th quarter. Nuveen Asset Management LLC now owns 4,154,771 shares of the biopharmaceutical company’s stock worth $40,468,000 after buying an additional 2,000,176 shares during the last quarter. Finally, Parametric Portfolio Associates LLC increased its position in Amicus Therapeutics by 18.3% during the first quarter. Parametric Portfolio Associates LLC now owns 192,799 shares of the biopharmaceutical company’s stock valued at $1,781,000 after acquiring an additional 29,880 shares during the last quarter.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Read More: Balanced Fund
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.